Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (Q45893877)
Jump to navigation
Jump to search
scientific article published on 4 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). |
scientific article published on 4 November 2015 |
Statements
1 reference
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (English)
1 reference
Elizabeth M Jaffee
1 reference
Dung T Le
1 reference
Todd S Crocenzi
1 reference
Jennifer N Urum
1 reference
Eric R Lutz
1 reference
Daniel A Laheru
1 reference
Elizabeth A Sugar
1 reference
Robert H Vonderheide
1 reference
George A Fisher
1 reference
Andrew H Ko
1 reference
Aimee L Murphy
1 reference
Katherine McDougall
1 reference
Sandy Ferber
1 reference
Dirk G Brockstedt
1 reference
4 November 2015
1 reference
1 reference
3
1 reference
P155-P155
1 reference
Suppl 2
1 reference
Identifiers
1 reference
1 reference